Lynparza significantly delayed disease progression as 1st-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer
Phase III POLO trial met its primary endpoint of progression-free survival AstraZeneca and MSD’s Lynparza is the first PARP inhibitor to demonstratebenefit in gBRCAm metastatic pancreatic cancer in a Phase III trialAstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced positive results from the Phase III POLO trial. Results from the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with Lynparza (olaparib) vs. placebo. The safety and tolerability profile